Gilead Sciences Inc (GILD)vsSandisk Corp (SNDK)
GILD
Gilead Sciences Inc
$137.21
-2.76%
HEALTHCARE · Cap: $170.34B
SNDK
Sandisk Corp
$709.71
-8.08%
TECHNOLOGY · Cap: $104.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Gilead Sciences Inc generates 230% more annual revenue ($29.44B vs $8.93B). GILD leads profitability with a 28.9% profit margin vs -11.7%. GILD earns a higher WallStSmart Score of 72/100 (B).
GILD
Strong Buy72
out of 100
Grade: B
SNDK
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.3%
Fair Value
$299.95
Current Price
$137.21
$162.74 discount
Intrinsic value data unavailable for SNDK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 37.4%
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Earnings expanding 23.4% YoY
Strong operational efficiency at 35.5%
Revenue surging 61.2% year-over-year
Earnings expanding 618.0% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Areas to Watch
4.7% revenue growth
Trading at 10.3x book value
Grey zone — moderate risk
ROE of -9.4% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : GILD
The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.
Bull Case : SNDK
The strongest argument for SNDK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 61.2% demonstrates continued momentum.
Bear Case : GILD
The primary concerns for GILD are Revenue Growth.
Bear Case : SNDK
The primary concerns for SNDK are Price/Book, Altman Z-Score, Return on Equity.
Key Dynamics to Monitor
GILD profiles as a value stock while SNDK is a hypergrowth play — different risk/reward profiles.
SNDK is growing revenue faster at 61.2% — sustainability is the question.
GILD generates stronger free cash flow (3.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GILD scores higher overall (72/100 vs 49/100), backed by strong 28.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Sandisk Corp
TECHNOLOGY · COMPUTER HARDWARE · USA
Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?